FDA AI & mRNA Politics: Pharmalittle News
- The Food and Drug Administration has introduced a generative artificial intelligence tool, Elsa, designed to accelerate regulatory reviews.
- However,some FDA employees have described the launch as rushed,expressing concerns about overblown capabilities and a lack of sufficient safeguards.
- Separately, the Department of Health and Human Services has submitted proposed guidance regarding the use of rebates in the 340B Drug Discount Program.
The FDA is shaking up regulatory processes! They’ve launched Elsa,a groundbreaking AI tool designed to expedite reviews. Though, concerns arise regarding its capabilities and safeguards. Together, HHS proposes guidance on 340B drug Discount Program rebates, sparking a review by the OMB. This is all happening before a June 30th deadline.This news, broken down by News Directory 3, unveils the FDA’s innovative use of artificial intelligence and the evolving landscape of drug pricing. The implications of these changes extend far beyond, shaping the future of healthcare regulations and perhaps impacting the availability and cost of pharmaceuticals. Discover what’s next for the FDA and the 340B program.
FDA Launches AI Tool; HHS Submits 340B Rebate Guidance
The Food and Drug Administration has introduced a generative artificial intelligence tool, Elsa, designed to accelerate regulatory reviews. The launch occurred ahead of a june 30 deadline. FDA Commissioner Mark Makary told employees the AI tool could expedite clinical protocol review and reduce the time to complete scientific review.
However,some FDA employees have described the launch as rushed,expressing concerns about overblown capabilities and a lack of sufficient safeguards. The agency said the AI can summarize adverse events, perform label comparisons, and generate code for databases.
Separately, the Department of Health and Human Services has submitted proposed guidance regarding the use of rebates in the 340B Drug Discount Program. It is indeed unclear when the guidance will be finalized and made public. The Office of Management and Budget has up to 90 days for its initial review.
This action follows a ruling by a Washington, D.C., federal district court that HHS has the authority to pre-approve 340B rebate models proposed by drugmakers. The May 15 decision prevents drug manufacturers from unilaterally converting upfront 340B discounts to rebates, but HHS could approve certain rebates in the future.
What’s next
The OMB review of the HHS guidance will determine the timeline for potential changes to the 340B Drug Discount Program. The FDA will monitor the performance and impact of its new AI tool,Elsa,on regulatory processes.